Hodgkin Lymphoma News and Research

RSS

New microfluidic device may help clinicians to improve cancer therapy

Manipulation of cells by a new microfluidic device may help clinicians improve a promising cancer therapy that harnesses the body's own immune cells to fight such diseases as metastatic melanoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and neuroblastoma.

3 Mar 2011

Night shift work may reduce risk of skin cancer in women

Melatonin is known to have cancer-protective properties, and shift work can induce desynchrony of the circadian system, reducing melatonin production. Shift work has been thought to have important health impacts, with evidence linking shift work to an increased risk of several cancers including breast, endometrial, prostate, and colorectal, and non-Hodgkin lymphoma.

2 Mar 2011

Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin in combination with chemotherapy for the treatment of newly diagnosed systemic anaplastic large cell lymphoma patients.

1 Mar 2011

Daiichi Sankyo enters merger agreement to acquire Plexxikon

Plexxikon Inc. today announced it has entered into a merger agreement with Daiichi Sankyo Company, Limited, a Japan-based global pharmaceutical company.

28 Feb 2011

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Seattle Genetics, Inc. announced today that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for the use of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma.

28 Feb 2011

Gilead Sciences signs definitive agreement to acquire Calistoga for $375 million

Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.

22 Feb 2011

CTI's fourth quarter net loss increases to $34.1 million

Cell Therapeutics, Inc. today reported recent accomplishments and financial results for the fourth quarter and year ended December 31, 2010.

16 Feb 2011

Combined chemotherapy and radiation therapy effective against Hodgkin's lymphoma, in the short term

Modern treatment for early stage Hodgkin's lymphoma is highly effective, leaving most patients with no evidence of cancer. However, experts differ on the best approach: Is chemotherapy enough or does adding radiation therapy improve the outcome?

16 Feb 2011

Halozyme-Roche announce initiation of Phase 3 subcutaneous MabThera trial in follicular NHL

Halozyme Therapeutics, Inc. and Roche today announced the first patient received subcutaneous MabThera (rituximab), an anticancer biologic, in a Phase 3 registration trial using Enhanze technology.

16 Feb 2011

Screening breast MRIs can detect invasive cancers in women with history of chest irradiation

Breast cancer screening with MRI can detect invasive cancers missed on mammography in women who've undergone chest irradiation for other diseases, according to a new study published online and in the April print edition of Radiology.

15 Feb 2011

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

Millennium: The Takeda Oncology Company today announced that Phase II results of a clinical trial examining VELCADE (bortezomib) in patients with previously untreated aggressive lymphoma were published in the Journal of Clinical Oncology.

5 Feb 2011

Immunomedics reports net loss of $3.4M in total revenues for second quarter 2011

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported financial results for the second quarter ended December 31, 2010.

5 Feb 2011

Treg therapy ensures success of hematopoietic stem cell transplantation, without triggering GVHD

For blood cancer patients at high risk of relapse, hematopoietic stem cell transplantation (HSCT), the transplantation of blood-forming stem cells, is one of best options for treatment and a potential cure. Unfortunately, the most common complication of HSCT is graft-versus-host disease (GVHD), a serious and often deadly post-transplant complication that occurs when the newly transplanted donor cells recognize the recipient's own cells as foreign and react by attacking the cells in the patient's body.

4 Feb 2011

Novel personalized therapy could treat metastatic melanoma and metastatic synovial cell sarcoma

Researchers have found that a novel form of personalized therapy that genetically engineers a patient's own anti-tumor immune cells to fight tumors could treat metastatic melanoma and metastatic synovial cell sarcoma, representing a potentially new therapeutic approach against these and other cancers.

1 Feb 2011

Researchers to develop computer-assisted diagnosis tools for pathologists

Researchers are leveraging Ohio Supercomputer Center resources to develop computer-assisted diagnosis tools that will provide pathologists grading Follicular Lymphoma samples with quicker, more consistently accurate diagnoses.

31 Jan 2011

FDA reports possible association between breast implants, ALCL

The U.S. Food and Drug Administration reported on January 26 that "a possible association between saline and silicone gel-filled breast implants and anaplastic large cell lymphoma, a very rare type of cancer. Data reviewed by the FDA suggests that patients with breast implants may have a very small, but significant risk, of ALCL in the scar capsule adjacent to the implant.

29 Jan 2011

Plexxikon begins PLX5622 Phase 1 trial in patients with rheumatoid arthritis

Plexxikon today announced that dosing began in the first of two Phase 1 clinical trials with PLX5622, a novel, oral and highly selective Fms inhibitor, targeted for the treatment of rheumatoid arthritis.

27 Jan 2011

Emergent BioSolutions initiates TRU-016 Phase Ib/II study for chronic lymphocytic leukemia

Emergent BioSolutions Inc. today announced the initiation of a Phase Ib/II study (16201) of TRU-016 for chronic lymphocytic leukemia (CLL). TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP™) protein therapeutic in development for the treatment of B-cell malignancies. TRU-016 is being developed in collaboration with Abbott.

25 Jan 2011

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Thursday, January 20, 2011, it submitted a Post Approval Supplement containing data supporting the removal of the Indium-111 ZEVALIN® pre-treatment imaging evaluation, more commonly referred to as the "bioscan" requirement.

24 Jan 2011

4SC initiates dosing in resminostat Phase I/II SHORE study for KRAS-mutant colorectal cancer

4SC AG, a drug discovery and development company, today announced that the first patient has been dosed in the Phase I/II SHORE study with the oral pan-histone deacetylase (HDAC) inhibitor resminostat as a second-line treatment for patients with advanced and metastatic colorectal KRAS-mutant cancer.

20 Jan 2011

Hodgkin Lymphoma News and Research

New microfluidic device may help clinicians to improve cancer therapy

Night shift work may reduce risk of skin cancer in women

Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL

Daiichi Sankyo enters merger agreement to acquire Plexxikon

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Gilead Sciences signs definitive agreement to acquire Calistoga for $375 million

CTI's fourth quarter net loss increases to $34.1 million

Combined chemotherapy and radiation therapy effective against Hodgkin's lymphoma, in the short term

Halozyme-Roche announce initiation of Phase 3 subcutaneous MabThera trial in follicular NHL

Screening breast MRIs can detect invasive cancers in women with history of chest irradiation

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

Immunomedics reports net loss of $3.4M in total revenues for second quarter 2011

Treg therapy ensures success of hematopoietic stem cell transplantation, without triggering GVHD

Novel personalized therapy could treat metastatic melanoma and metastatic synovial cell sarcoma

Researchers to develop computer-assisted diagnosis tools for pathologists

FDA reports possible association between breast implants, ALCL

Plexxikon begins PLX5622 Phase 1 trial in patients with rheumatoid arthritis

Emergent BioSolutions initiates TRU-016 Phase Ib/II study for chronic lymphocytic leukemia

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

4SC initiates dosing in resminostat Phase I/II SHORE study for KRAS-mutant colorectal cancer

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News